Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.

Blood
Ruben MesaAyalew Tefferi

Abstract

Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT). All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), M0 (22.4%), and M2 (17.9%). Cytogenetic studies during LT were available in 56 patients and revealed a clonal abnormality in 51 (91%): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormalities of chromosome 5 or 7. Karyotypic evolution was documented in the majority of the patients in whom serial analysis was possible. In general, LT was fatal in 98% of the cases after a median of 2.6 months (range, 0-24.2 months). Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%. The remaining 67 patients received either supportive care alone (48 patients) or low-intensity chemotherapy (19 patients). Overall, survival was similarly poor in all 3 treatment categories. The outco...Continue Reading

References

Dec 1, 1988·British Journal of Haematology·G BarosiE Ascari
Apr 27, 2000·The New England Journal of Medicine·A Tefferi
May 25, 2001·International Journal of Hematology·T OkamuraH Mizoguchi
May 31, 2001·British Journal of Haematology·A TefferiG W Dewald
Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Aug 16, 2003·Blood·H Joachim DeegFrederick R Appelbaum

❮ Previous
Next ❯

Citations

Mar 1, 2008·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Rakhee KarHara P Pati
Sep 4, 2012·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Rodrigo Lopes da Silva
Aug 30, 2005·The American Journal of Pathology·Alessandro M VannucchiFrancesco Paoletti
Jan 11, 2008·Leukemia·N Kröger, R A Mesa
Dec 7, 2006·AIDS·Mireille CentlivreBen Berkhout
Oct 25, 2008·Annual Review of Medicine·Omar I Abdel-Wahab, Ross L Levine
Dec 10, 2013·Hematology·Olatoyosi Odenike
Apr 17, 2007·Blood·George L Chen, Josef T Prchal
May 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Magnus BjörkholmOla Landgren
Mar 23, 2011·Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology·Rodrigo Lopes da SilvaAida Botelho de Sousa
Jul 17, 2012·Leukemia & Lymphoma·Ruben A Mesa
Jun 19, 2013·Leukemia & Lymphoma·Jyotsna MehtaRuben Mesa
Nov 17, 2006·Leukemia & Lymphoma·Graziana FamosoClaudio Doglioni
Dec 3, 2005·Leukemia & Lymphoma·Min-Ling LiuMetin Ozdemirli
Dec 3, 2005·Leukemia & Lymphoma·Maria E Nelson, David P Steensma
Nov 22, 2011·Leukemia & Lymphoma·Grzegorz HelbigSławomira Kyrcz-Krzemien
Oct 3, 2013·Expert Review of Hematology·Claire HarrisonSrdan Verstovsek
Jul 15, 2015·Expert Opinion on Emerging Drugs·Holly L Geyer, Ruben A Mesa
Sep 21, 2012·Expert Opinion on Investigational Drugs·Raoul TibesRuben A Mesa
Jun 26, 2009·Expert Opinion on Emerging Drugs·Ruben A Mesa, Ayalew Tefferi
Sep 1, 2007·Expert Opinion on Medical Diagnostics·Brijesh Arora, Ayalew Tefferi
Jun 7, 2012·Expert Opinion on Investigational Drugs·Ali Tabarroki, Ramon V Tiu
Dec 18, 2014·Proceedings of the National Academy of Sciences of the United States of America·Raajit RampalRoss L Levine
Jul 18, 2015·American Journal of Clinical Pathology·Magdalena Czader, Attilio Orazi

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.